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This work reviews results of in vivo dosimetry (IVD) for total skin electron beam (TSEB)
therapy, focusing on new methods, data emerged within 2012. All quoted data are based
on  a careful review of the literature reporting IVD results for patients treated by means
of  TSEB therapy. Many of the reviewed papers refer mainly to now old studies and/or old
guidelines and recommendations (by IAEA, AAPM and EORTC), because (due to intrinsic
rareness of TSEB-treated pathologies) only a limited number of works and reports with a
large  set of numerical data and proper statistical analysis is up-to-day available in scientiﬁcIn vivo dosimetry
Total skin electron beam therapy
Systematic review
literature. Nonetheless, a general summary of the results obtained by the now numerous
IVD techniques available is reported; innovative devices and methods, together with areas of
possible further and possibly multicenter investigations for TSEB therapies are highlighted.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
TSEB therapy by involved care center and professionals. At any1.  Background
In last decades, TSEB has become an important medical
service for the treatment of rare skin malignancies (see
references in5,10 for historical background). On the basis of epi-
demiological data, only a low percentage of patients need this
kind of treatments; anyway, various rare skin diseases such
as mycosis fungoides, T-Cell lymphoma, Sèzary syndrome,
Kaposis sarcoma and inﬂammatory breast cancer are usually
treated with TSEB.20 Related uncommon setup42 evaluation
and special tools requirements, which need to be imple-
mented for successful treatments were already described
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1507-1367/$ – see front matter © 2013 Greater Poland Cancer Centre. Publish
http://dx.doi.org/10.1016/j.rpor.2013.07.011by major reports and available guidelines.1 At present, in-
depth explanation of the process of commissioning and
evaluation is already available, with due mathematical formal-
ism for proper dose calculations2,3; moreover, preliminarily
needed measurements have been extensively described, and
related in vivo dosimetry problems discussed in detail.3,4 Many
approximations and relatively large tolerance levels concern-
ing the results obtained by in vivo measurements are to be
ordinarily expected and commonly accepted in the course ofahoo.com (G. Guidi), Gottardi.Giovanni@policlinico.mo.it
oliclinico.mo.it (T. Costi).
rate, suitable in vivo dosimetry measures must be provided for
safety treatment procedure and the bulk of data here reviewed
conﬁrm the need of these procedures for such complex
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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echniques as the ones involved in TSEB treatments. Specif-
cally, many  works and authors (see e.g.4,26,28 and references
herein) report in vivo dosimetry as a must for TSEB therapy
or:
 providing objective data for the radiation oncologist;
 prescribing supplemental ﬁelds of treatment;
 avoiding possible toxicity areas and infections that could
have severe implications for patients Quality of Life (QoL)
and patients follow-up.
.  Systematic  review  of  literature  criteria
ur method of bibliographic search and systematic review
ade use of Medline, Cochrane Library and Science Direct search
ngines for the major clinical relevant articles and Medical
hysics and JACMP  for speciﬁc physics articles. Using proper
ey words (see above Abstract), the temporal range 2000–2012
as imposed as a constraint. We also extended our search to
nclude the main guidelines and reports available from IAEA,
STRO, AAPM and ESTRO. Additional studies were included
fter the bibliographic search, using both our professional
nowledge and advice by other experts of TSEB sector to
rovide more  exhaustive data and/or mention of innovative
pproaches in TSEB ﬁelds. General search map  and results
re detailed in Graph 1. Basically, only papers dealing with
esults of patient treatments were considered. Many arti-
les discussing only phantom simulation and/or techniques
f implementation were not considered as a main topic of
he present review. In the absence of comparative data of
n vivo dosimetry, measurement techniques with innovative
pproach was considered as an ‘extra inclusion’ criterion. In
ll, we  tried to report mainly studies with patient data, but
ithout advancing any interpretation about clinical relevance
nd without favoring any personal judgment about measure-
ent techniques. Due to the limited number of publications,
uring our systematic review we  included some other papers,
eports and guidelines with evaluation of the articles reporting
ata of in vivo dosimetry applied to the TSEB, not reachable by
he above-mentioned libraries, but currently available by the
oogle Scholar engine.
Finally, data for each study were reported in separate evi-
ence in a synoptic table (Table 1). Following above-speciﬁed
ationale, our in vivo results summarizing table include:
uthors; number of treated patients with in vivo data (when-
ver reported); number of measure points over the patients
kin; the kind of IVD detectors or devices used; the irradia-
ion technique adopted in treatments; and an indication of
he results obtained by the studies as their conclusions.
.  Materials  and  methods
ifferent approaches and strategies to deliver TSEB therapy
re described in literature (for a review, see45 and references
herein): rotational TSEB, multiple ﬁeld techniques (Stanford
echnique)7, single scatterer horizontal beam, translational
echniques, patient lying on technique and possible combi-
ation of these techniques.11,19,20 Each modality of deliverytherapy 1 9 ( 2 0 1 4 ) 144–150 145
requires accurate calibration and evaluation of the IVD data,
as this kind of dosimetry has become a routine procedure for
many  centers providing TSEB therapy. Anyway, due to large
ﬁelds of irradiation used in therapy and the multiplicity of
involved and/or emerging techniques, the determination of
the absolute dose delivered for speciﬁc anatomical site may
often require speciﬁc evaluation and proper rationale concern-
ing the obtained results.
Best results for IVD were obtained in past years by thermo-
luminescent dosimetry (TLD) and ﬁlm dosimetry.5,6,11,15,21
Recently, new devices and related dosimetric techniques have
appeared (radiochromic ﬁlms,14 MOSFET detectors24 diodes
and optically stimulated luminescent (OSL) devices18,22)
highlighting some important advantages (such as two-
dimensional mapping apart from other opportunities) of new
technologies over more  traditional ones, mostly in associ-
ation with new IVD techniques. But some cautions are to
be taken into considerations in order for the new IVD tech-
niques and new devices to actually overcome and substitute
the more  traditional ones. For example, different and some-
times even conﬂicting conclusions from many  authors are
reported about the use of the radiochromic ﬁlm. Some groups
report evidence of good agreement between measure with TLD
and Gaf-chromic ﬁlm,14,16,19,44 but some groups call for more
caution and conclude with the need of requirements for fur-
ther or deeper investigation in particular for large variation
due to low dose exposures.16,23 Few of the scientiﬁc papers
available describe Monte Carlo calculations (see e.g.43) as an
alternative or to conﬁrm TSEB in vivo ﬁlm dosimetry; but
Monte Carlo simulations appear to be still far from taking into
affordable account complex details, like room geometry and
different off-axis distances.13,22 Moreover, both simulations
and observed measures may have inaccuracies, due to intri-
cate details (patient skin distance variations, patient motion
and inappropriate setup, which could actually account for
the discrepancies between simulation and IVD results. Major
faults of the IVD devices traditionally used for TSEB therapy
are related to their lack of real-time measurements. Mostly
because of the delay between exposure and reading time,
usual IVD devices and techniques are highly time consum-
ing in terms of calibration, pre-irradiation or preparation. The
evolution of new medical devices will allegedly open new areas
of investigation, providing actual real-time IVD for TSEB (and
in total body irradiation as well). For example, some institu-
tions have explored IVD using OSL or MOSFET as a pioneering
approach to patient safety protection instead of reserving
them only for radiation protection.24,34–36 The integration of
related data with routine tools and other medical devices
could undeniably open new frontiers for in vivo dosimetry. We
actually report here some experiences of IVD for TSEB using
semiconductor diode technology,1,8,9 although some authors
conclude that these devices, contrary to some suggestions,
could be actually convenient for real-time dose delivery ver-
iﬁcation, but with some anomalies.8 Anyway, it is evident
that extensive reference to measurements using TLD remains
necessary to reliably evaluate dose distribution, to discover
the overlapping of dose and to demonstrate the effective-
ness of delivered dose. Excluding the IVD studies using TLD,
many of the alternative papers about new in vivo dosime-
try tools still concern a too restricted number of patients and
146  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 144–150
he liGraph 1 – Systematic review of t
measures to ensure robust effectiveness and efﬁciency of new
IVD methods. Finally, still very few experiences are reported,
concerning TSEB therapy for infants (anyway, see21 and refer-
ences therein).4.  Results
During the last decade, because of the patients safety
approach of their centers, many  authors have shown a great
Table 1 – Review of the results of in vivo dosimetry for patients
Authors (years) No. patients Proposed
No. of
readings
Antolak et al. (1998) 72 patients 22 points 
Yaparpalvi et al. (2000) 360 patients 809 in vivo dose
measurements
Anacak (2003) 67 patients 10 points 
Piotrowski et al. (2003) 3 patients 736 points (34
points/patient)
Marre and Marinello (2004) n.a. 20 fractions 
Gamble et al. (2005) 2 patients n.a. 
Piotrowski et al. (2006) 3 patients 22 points (proposed
by Antolak)
12 points (proposed
by other authors)
Bufacchi et al. (2007) 4 patients 20 points (TLD)
6 points
(Gaf-chromic vs.
TLD)
Xu et al. (2008)17 1 patient n.a. 
Poli et al. (2010) n.a. n.a. 
Al-Mohammed et al. (2011) 6 patients 10 
Bao et al. (2012) 2 infants 12 points 
n.a., not available.
a Mean deviation of all measurements.terature and adopted keywords.
interest in in vivo dosimetry procedures and problems in
TSEB treatments. Replacement of complex and long manage-
ment required by the traditional use of TLD still remains the
aim of many  studies in order to replace old rigid approaches
with more  ﬂexible and less time-consuming solutions. Some
authors conclude that innovative device and new methods
of IVD could actually be integrated with other systems and
software already available, such as e-chart and speciﬁc soft-
ware  for IVD database.18 In our opinion, comparisons of
 treated with TSEB therapy.
In  vivo
dosimetry
device(s)
Irradiation
technique
Main
results
TLD 6 static dual
ﬁelds + scatter plate
Tables 3 and 4 in
Ref.5
Diode detectors n.a. 11.5% of the
measurements
outside the
threshold of ±6%
TLD 6 static dual ﬁelds ±15.4%a
TLD Rotational ±10%
p-Type diode n.a. ±1%
Film Gaf-chromic 6 static dual ﬁelds ±10% of the
prescription
TLD  Rotational dual
ﬁelds + scatter plate
See Table 3 in Ref.15
TLD ﬁlm
Gaf-chromic
6 static dual ﬁelds TLD: ±1.8%
Film: ±3.7%
MOSFET Rotational ±5%
TLD ±6.5 to ± 50%
MOSFET Stanford
twelve-ﬁelds
±5.5%
OSL Rotational ±10% of the
prescription
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ew techniques for IVD still assess TLD measures as a gold
tandard. When new methods (OSL, MOSFET, Gaf-Chromic)
re uncritically used, possible bias of statistical analysis could
e introduced, primarily because of the low level of statistical
ata available so far. An alternative could be the introduc-
ion of Monte Carlo cross-reference calculations but (as above
entioned) it is reported that many  factors can inﬂuence dose
alculations, thereby inducing almost unavoidable discrepan-
ies with in vivo measures.13
On the other hand, there is a tendency to cite only advan-
ages of new techniques, thereby partially hiding problems
hich are still relevant and connected to them. It should be
nderlined that data coming from new techniques could be
isinterpreted and could underestimate the criticality of the
n vivo dosimetry and the possible effects of irradiation on
atients. In addition to this, it is not often easily identiﬁ-
ble, if the improvements of the IVD techniques using new
evices are actually correlated with the new practice, or if they
ould be simply considered as statistical events related to the
mall number of patients analyzed. Nonetheless, these new
ptions can be considered, with a proper degree of caution,
or commissioning purposes and cross-reference techniques
alidation.
To minimize, to prevent and possibly to avoid toxicity and
o help proper evaluation of undesirable effects, each IVD pro-
edure should be accurate and as reproducible as possible
uring the entire course of treatments; especially in infants,
nd wherever clinical need demands for additional irradia-
ion above all, e.g. using local ﬁelds. New IVD techniques and
evices have not yet been extensively used to monitor (late)
oxicity effects, and it is not possible to identify on the basis
f published studies if identical anatomical regions of analy-
is have actually been considered. Most of the recent studies
ake use of new in vivo devices in the region of uniformity or
n position of excellent geometry with respect to the electron
eams. But it is known that some of the criticality for the elec-
ron dose calculation and/or dose deposition is induced by the
resence of cavities and/or by irregular body shape. Mapping
n of phantom-surface dose distributions is actually available
oth for rotational partial skin electron irradiation39 and for
eneral TSEB,40,41 whereas in vivo dose variations with depth
nd body locations during TSEB are almost systematically
eported in cited papers, but usually only for measurements
ith traditional TLD dosimeters. At any rate, dose uniformity
emains difﬁcult to reach, because of the varying curvature of
ody surface over the stray ﬁeld14,25,27 and some parts of the
atient body can of course shield other parts. The main solu-
ion to assure, even in those locations, the prescribed dose
omogeneity within proper limits (say, around reference lim-
ts of ±10%) is to carry out proper (and possibly real-time) in
ivo measurements during patient irradiation.
A great part of recent IVD studies displays a major bias
ue to unavoidable reduced statistical numerousness of data
nd measures on patients, because of the intrinsic rareness of
BET cared pathologies.14,16,19 As reported in Table 1, only few
tudies report a large number of cases, specifying number of
atients and number and location of points of measure over
atient skin. Moreover, only a few authors have given details
bout IVD accuracy, correlation with speciﬁc anatomy position
nd error associated with speciﬁc points of measure. In thistherapy 1 9 ( 2 0 1 4 ) 144–150 147
way, a further small bias into the statistical results is prob-
ably introduced, due to the indetermination of the points of
measure. For example, TLD techniques have already reported
many  discrepancies between the dose planned and the dose
delivered for speciﬁc anatomical areas,15 but analogous data
are not yet available for newer in vivo devices and techniques.
When measurements are performed, problems of
over/under dosage can obviously appear due to inhomo-
geneities in air cavities (e.g. ears) or behind bone structures
(e.g. mouth). In these cases in vivo dosimeters should be
used with extreme care. Detailed investigations reveal that
many dose discrepancies are due to inaccurate IVD device
orientation and positioning, especially in the regions with
rapidly changing contours and/or sloping surfaces. Relying on
the solid base of TLD measures of the last decades, it is now
possible to identify the body part with maximal criticalities.
Some authors, using TLD in vivo dosimetry, actually report
critical dose distribution related to the position of the TLD:
particularly for the scalp, hands, biceps, shoulder, perineum,
feet and ﬁnger; the same complications during IVD proce-
dures using new devices are only partly described. Thus,
hypotheses about new IVD protocols and related devices
should take into consideration these previous experiences
and reproduce analogous and expectedly better results before
being routinely implemented12,23,25 (and references therein).
5.  Discussion
In vivo dosimetry has as its justiﬁcation principles both the
safety of patients and the reduction of possible errors. One
major aim of the in vivo dosimetry process is to provide
the correct information of the cumulated dose during radi-
ation treatment and, if possible, to monitor in real-time the
dose delivered. Safety procedures and commissioning are
detailed in depth in many  reports and guidelines for the
use of external radiation therapy with electrons (e.g. AAPM,
ESTRO, IAEA).1–4 The health risk management has developed
statistical analysis to evaluate the procedure performance
and safety (e.g. FMEA/FMECA and RCA; see28–31) to prevent
incorrect administration of complex procedures to patients
resulting from direct/indirect improper interventions and/or
errors. This could reasonably be prevented not only by the use
of proper in vivo techniques, but even with the build up of ade-
quate staffs with adequate training and/or license to perform
these complex procedures. Obviously, all of these should be
associated with adequate calibration, careful commissioning,
adequate QA programs, speciﬁc training and in-depth knowl-
edge of the adopted TSEB therapy technique(s). Adverse risks
related to wrong or improper TSEB delivery can always appear,
due to improper use or absence of professionals for in vivo
dosimetry or to underestimation of the importance of these
tasks during the treatment sessions.
The review of the TSEB/IVD results should also be discussed
in depth and proved by mutual (possibly, by multi-center) stud-
ies, to determine actual accuracy and to shape standards of
in vivo doses for TSEB treatments. Some groups have already
tried to interrelate and inter-evaluate performances for TSEB
therapy and IVD techniques, but they have concluded that
occurring ascertained variations in dose distribution among
d rad148  reports of practical oncology an
different TSEB treatment techniques require further investi-
gation, which should include clinical evidence and practical
considerations.23
Most of the authors quoted in Table 1, according to TLD
in vivo measurement, agree to the tolerance range of ±10% of
the TSEB therapy prescribed dose. The new above-mentioned
techniques of IVD seem (see Table 1) apt to promise a much
greater accuracy (±1% for p-type diode12 up to ±5.5% for
MOSFET24). Anyway, to obtain new measure (gold) standards
and to avoid possible unexpected results or toxicity, new
methods and devices need to be further investigated and vali-
dated, with more  statistical data relying on precise indication
of the anatomical skin points/regions of measure.
As widely recommended in guidelines and reports, the use
of boost ﬁelds requires careful clinical judgment based on
in vivo dosimetry15 (and references therein), because wrong
or inappropriate information could originate misjudgments
and causeless skin lesions. Skin dose associated with radiation
therapy is of course of primary interest in clinical evaluation
and for investigation about possible risks of late effects. But
it should be always taken into considerations that skin dose
is in no way an intuitive matter and it is difﬁcult to mea-
sure. Even here, literature is supported by some Monte Carlo
simulations13; nonetheless, at least the above-mentioned
native problems of the TSEB techniques require to be prop-
erly solved, before thinking about greatly reducing the need of
in vivo measurements. At present, using a set of general rules,
equations and models, skin dose can be estimated with rea-
sonable accuracy for patients receiving in-depth radiotherapy;
of course, related safety standards and follow up protocols
must be extended to TSEB techniques. It should be under-
lined that in vivo dosimetry cannot by itself alone guarantee the
TSEB optimality: patient safety and consent should be attested
by both mandatory dosimetry protocols and medical physics
consultations. Of course, appropriate safety checks and real-
time acknowledgment could minimize some of the risks of
inappropriate patient TSEB treatments. Thus, therapists must
always supervise patients during treatments, both visually –
by carefully oriented closed circuit and television camera(s)
and by proper speak/audio communication system with the
patient inside the bunker. Finally, patients condition must be
assessed by radiation oncologist during the entire course of
treatment to manage and possibly to prevent any acute toxic-
ity with the aid of IVD data evaluation, to provide care support,
and to take shared decisions about patch treatments and/or
any other TSEB-feasible technical option.
6.  Measurement  tools  for  in  vivo  TSEB
conditions:  an  overview
During many  years (starting from the eighties), in vivo TSEB
dosimetry has concentrated upon clinical use of thermolumi-
nescent dosimeters and – somewhat later – diode dosimeters
(see Van Dam and Marinello,4 chapters III and IV for an
extended review; Furetta and Weng32 for a comprehensive
description of the dosimetric technique; and Furetta33 for
a general physical treatise about this mostly consolidated
technique). More  recent dosimetric alternatives (and more
expensive too, but usually much less cumbersome and muchiotherapy 1 9 ( 2 0 1 4 ) 144–150
less time-consuming, particularly in comparison with ther-
moluminescent dosimeters) are given by MOSFET Dosimeters
(see Bloemen-van Gurp – particularly Chapter 3 – for an
extended Review about the use of MOSFET devices34), by opti-
cally stimulated dosimeters (OSL) (see Esquivel et al.35 for
general IVD using these devices; and Viamonte et al.36 for
an example of a commercially available OSL system, used for
general external beam radiotherapy) and by electron para-
magnetic resonance (EPR) dosimeters (see Shultka el al. for the
comparison between l-alanine EPR dosimetry measurements
and data from a clinical TPS, reporting discrepancies within a
range of about 0.6%37; and Schauer et al. for a general review
of this technique in medical dosimetry38).
7.  Conclusions
Our review of the results for in vivo dosimetry in TSEB therapy
has shown that many  topics still remain under investiga-
tion. The advent of methods for real-time dosimetry and the
availability of more  user-friendly and/or simpler devices have
opened new perspectives in related medical physics area. As
a further perspective, technical problems could be solved by
networks of hospitals over regional area, possibly providing
remote reading of instruments and tools with direct network
data access by professionals, thereby greatly helping future
shaping of newly coded procedures. These advantages could
spread and expand new techniques – and possibly a renewed
use of the old ones – to more  centers, as the demand for TSEB
techniques, due to remembered rareness of related patholo-
gies, remains very limited. To possibly overcome problems of
limited number of cases and related poor statistical signiﬁ-
cance (particularly for more  recent and new techniques IVD
results), both national and international collaboration should
be claimed and arranged.
Most of the TSEB irradiation centers have locally solved
some problems of in vivo dosimetry and many  authors have
explored new approaches and methods in order to be both
ﬂexible and accurate, to provide the radiation oncologist with
the correct information for adequate dose assessments and
care planning, and in order to standardize the techniques and
methods for in vivo dosimetry. It must be remarked that the
introduction of the MOSFET, semiconductor diodes and OSL
devices (with their small dimensions and possible isotropic-
ity with respect to the direction of incident beam) actually
allows the beginnings of real-time IVD dosimetry, otherwise
hardly possible (or impossible) to obtain with the TLD and
FILM techniques. These new IVD systems can be quickly read,
their data can be promptly integrated with chart, database
and spreadsheets for calculation, and their use can be further-
more  optimized by personnel and staff organization, using
coded procedures and adequate training for the operators. On
the same ground, these tools could actually even open new
landscapes for in vivo dosimetry, as they could be applied
in network of hospitals sharing devices and professionals,
thereby collecting data from multiple sites. Consequently,
these new options could also open opportunities for expand-
ing the TSEB irradiation therapies to a greater number of
sites and to standardize the procedures over wider regions
(thereby furthermore overcoming above-mentioned statistical
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umeracy problems). But before all of this is possible, the
fﬁcacy and accuracy of the new procedures, both in gen-
ral and special conditions must be robustly proved, so as
o adequately increase the reference data bases, hopefully
ecoming, as soon as possible, part of nationally and inter-
ationally available guidelines.
In complex treatments, such as the ones involved in
SEB, data from clinical evaluation about treated patients are
elf-evidently of crucial importance, especially in the imple-
entation of new methods and devices, with the constant
im of avoiding possible and/or unexpected late effects, due to
nappropriate use of standardized techniques. In this respect,
t is noticeable that wherever a TSEB therapy medical service
s provided, most of the procedures are already supported
ith extensive commissioning, QA programs and in vivo
easurements for safety purpose and accurate dose deliv-
ry. Moreover, currently, many  organizations already include
nternational-protocols-for-electron-beams based IVD, as a
ust for their TSEB therapy treatments. To avoid critical
vents, inefﬁcacy and/or inefﬁciency of the TSEB techniques,
ll needed and/or useful information must be collected in
eams of dedicated professionals, thereby ensuring real use-
ulness of related in vivo dosimetry techniques. Facing speciﬁc
VD technical problems, wherever no guidelines exist or no
ther reliable sources are available, systematic reviews of pub-
ished clinical trials data and/or experts consensus, advice and
eview should be taken into consideration. Critical use of med-
cal textbooks, journals, articles and government publications
an be an acceptable and feasible solution as well.
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